Samalizumab binding dampens CD200 overexpression on CLL cells in a dose-dependent manner, and the reduction in CD200 expression is sustained at higher doses (300–500 mg/m2). The gene discussed is CD200; the disease is B-cell chronic lymphocytic leukemia.